Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Amortizatization of Intangibles (2020 - 2022)

IGC Pharma (IGC) has disclosed Amortizatization of Intangibles for 3 consecutive years, with $26000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Amortizatization of Intangibles changed 0.0% to $26000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $116000.0, a 107.14% increase, with the full-year FY2022 number at $115000.0, up 422.73% from a year prior.
  • Amortizatization of Intangibles was $26000.0 for Q3 2022 at IGC Pharma, down from $28000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $35000.0 in Q1 2022 to a low of -$2000.0 in Q3 2020.
  • A 3-year average of $19100.0 and a median of $26000.0 in 2021 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: skyrocketed 2600.0% in 2021, then changed 0.0% in 2022.
  • IGC Pharma's Amortizatization of Intangibles stood at $1000.0 in 2020, then surged by 2600.0% to $27000.0 in 2021, then decreased by 3.7% to $26000.0 in 2022.
  • Per Business Quant, the three most recent readings for IGC's Amortizatization of Intangibles are $26000.0 (Q3 2022), $28000.0 (Q2 2022), and $35000.0 (Q1 2022).